Welcome to our dedicated page for Ocuphire Pharma news (Ticker: OCUP), a resource for investors and traders seeking the latest updates and insights on Ocuphire Pharma stock.
Ocuphire Pharma reports developments for a clinical-stage ophthalmic biopharmaceutical business focused on small-molecule therapies for retinal and refractive eye disorders. Recurring news covers APX3330, an oral Ref-1 inhibitor in development for diabetic retinopathy, and Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size.
Company updates also address ophthalmology clinical trial data, RYZUMVI for pharmacologically induced mydriasis through a commercial partner, presbyopia and dim-light vision disturbance programs, scientific meeting presentations, financial results, capital-structure matters, shareholder votes, and governance disclosures.
Ocuphire Pharma, Inc. (Nasdaq: OCUP) will present at the Aegis Virtual Conference on May 7-9, 2024. Dr. George Magrath, CEO of Ocuphire, will provide an overview of the company's focus on developing therapies for eye disorders. Investors can arrange one-on-one meetings during the conference.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.